The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A dose-escalation study with the novel formulation of the oral pan-class I PI3K inhibitor BEZ235, solid dispersion system (SDS) sachet, in patients with advanced solid tumors.
J. D. Peyton
No relevant relationships to disclose
J. Rodon Ahnert
No relevant relationships to disclose
H. Burris
No relevant relationships to disclose
C. Britten
No relevant relationships to disclose
L. C. Chen
No relevant relationships to disclose
J. Tabernero
Consultant or Advisory Role - Novartis
V. Duval
Employment or Leadership Position - Novartis
N. Rouyrre
Employment or Leadership Position - Novartis
A. P. Silva
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
C. Quadt
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
J. Baselga
Consultant or Advisory Role - Novartis